Singson, Kyle Daniel C.
HRN: 22-33-88 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/21/2023
01/28/2023
IVTT
54mg
Q24
PCAP
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes